Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Updated Outcomes of Fludarabine/Melphalan/Bortezomib (Flu/Mel/Vel) Conditioning for Upfront Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma

Taiga Nishihori, MD, Claudio Anasetti, MD, Rachid Baz, MD, Jose L Ochoa-Bayona, MD, Kenneth H. Shain, MD PhD, Ryan Hillgruber, Melissa Alsina, MD

Blood (2016) 128 (22): 5885.

https://doi.org/10.1182/blood.V128.22.5885.5885

Published: 2016

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML) Not in First Remission

Kendra L Sweet, MD MS, Jeffrey E Lancet, MD, Ryan Hillgruber, BS, Megan Melody, MS, Amina Llishi, Janelle Perkins, PharmD, Hugo F. Fernandez, MD, Teresa Field, MD, PhD

Blood (2015) 126 (23): 4388.

https://doi.org/10.1182/blood.V126.23.4388.4388

Published: 2015

Journal Articles

A Phase 2 Study of High-Dose Melphalan Plus Bortezomib (Mel/Vel) Conditioning Followed By Autologous Hematopoietic Cell Transplantation in Myeloma

Taiga Nishihori, MD, Jose L Ochoa-Bayona, MD, Rachid Baz, MD, Kenneth H. Shain, MD PhD, Christine Simonelli, RN, Chiaka Nwoga, MPH, CCRP, Ryan Hillgruber, Daniel Sullivan, MD MS, Claudio Anasetti, MD, Melissa Alsina, MD

Blood (2014) 124 (21): 3987.

https://doi.org/10.1182/blood.V124.21.3987.3987

Published: 2014

Journal Articles

Does HLA-C Matching Predict the Engrafting Unit in Double Umbilical Cord Blood Transplants?: A Single Institution Retrospective Analysis

Michael T Tees, MD MPH, Brian C Betts, MD, Hugo F Fernandez, MD, Ryan Hillgruber, Ernesto Ayala, MD, Teresa Field, MD PhD, Mohamed A Kharfan-Dabaja, MD, Frederick L Locke, MD, Asmita Mishra, MD, Taiga Nishihori, MD, Jose L Ochoa-Bayona, MD, Lia Perez, MD, Joseph Pidala, MD PhD, Claudio Anasetti, MD, Marcie L Riches, MD MS

Blood (2014) 124 (21): 2475.

https://doi.org/10.1182/blood.V124.21.2475.2475

Published: 2014

Journal Articles

Cerebrospinal Fluid (CSF) Involvement By Plasma Cell Dyscrasias – Single Center Experience

Taiga Nishihori, MD, Jun Zhou, MD, Kenneth H. Shain, MD PhD, Rachid Baz, MD, Melissa Alsina, MD, Daniel Sullivan, MD MS, Ryan Hillgruber, Elizabeth M. Sagatys, MD, Lynn C. Moscinski, MD, Ling Zhang, MD

Blood (2014) 124 (21): 5686.

https://doi.org/10.1182/blood.V124.21.5686.5686

Published: 2014

Journal Articles

Evaluation Of Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes Of One Hundred Thirty-Two Patients With Myelodysplastic Syndrome (MDS) Or Chronic Myelomonocytic Leukemia (CMML) Up To Age Seventy-Five and The Effect Of Pre-Transplant 5-Azacitidine

Teresa Field, MD, PhD, Janelle Perkins, PharmD, Marcie Tomblyn, MD, MS, Ryan Hillgruber, Taiga Nishihori, MD, Asmita Mishra, MD, Joseph Pidala, MD, MS, Ernesto Ayala, MD, Frederick L Locke, MD, Melissa Alsina, MD, Brian C. Betts, MD, Eric Padron, MD, Hugo F Fernandez, MD, Jeffrey E Lancet, MD, Alan List, MD, Rami S Komrokji, MD, Mohamed A. Kharfan-Dabaja, MD, Claudio Anasetti, MD

Blood (2013) 122 (21): 2152.

https://doi.org/10.1182/blood.V122.21.2152.2152

Published: 2013

Journal Articles

Allogeneic Hematopoietic Cell Transplantation Using Fludarabine, Melphalan and Bortezomib (Flu/Mel/Vel) Conditioning For Consolidation Of VGPR Or CR In Myeloma

Taiga Nishihori, MD, Jose L. Ochoa-Bayona, MD, Kenneth H. Shain, MD, PhD, Daniel Sullivan, MD, Rachid Baz, MD, Ryan Hillgruber, Claudio Anasetti, MD, Melissa Alsina, MD

Blood (2013) 122 (21): 3390.

https://doi.org/10.1182/blood.V122.21.3390.3390

Published: 2013

NARROW

Updated Outcomes of Fludarabine/Melphalan/Bortezomib (Flu/Mel/Vel) Conditioning for Upfront Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma

Allogeneic Hematopoietic Stem Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML) Not in First Remission

A Phase 2 Study of High-Dose Melphalan Plus Bortezomib (Mel/Vel) Conditioning Followed By Autologous Hematopoietic Cell Transplantation in Myeloma

Does HLA-C Matching Predict the Engrafting Unit in Double Umbilical Cord Blood Transplants?: A Single Institution Retrospective Analysis

Cerebrospinal Fluid (CSF) Involvement By Plasma Cell Dyscrasias – Single Center Experience

Evaluation Of Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes Of One Hundred Thirty-Two Patients With Myelodysplastic Syndrome (MDS) Or Chronic Myelomonocytic Leukemia (CMML) Up To Age Seventy-Five and The Effect Of Pre-Transplant 5-Azacitidine

Allogeneic Hematopoietic Cell Transplantation Using Fludarabine, Melphalan and Bortezomib (Flu/Mel/Vel) Conditioning For Consolidation Of VGPR Or CR In Myeloma

Email alerts

ASH Publications

American Society of Hematology

Updated Outcomes of Fludarabine/Melphalan/Bortezomib (Flu/Mel/Vel) Conditioning for Upfront Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma

Allogeneic Hematopoietic Stem Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML) Not in First Remission

A Phase 2 Study of High-Dose Melphalan Plus Bortezomib (Mel/Vel) Conditioning Followed By Autologous Hematopoietic Cell Transplantation in Myeloma

Does HLA-C Matching Predict the Engrafting Unit in Double Umbilical Cord Blood Transplants?: A Single Institution Retrospective Analysis

Cerebrospinal Fluid (CSF) Involvement By Plasma Cell Dyscrasias – Single Center Experience

Evaluation Of Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes Of One Hundred Thirty-Two Patients With Myelodysplastic Syndrome (MDS) Or Chronic Myelomonocytic Leukemia (CMML) Up To Age Seventy-Five and The Effect Of Pre-Transplant 5-Azacitidine

Allogeneic Hematopoietic Cell Transplantation Using Fludarabine, Melphalan and Bortezomib (Flu/Mel/Vel) Conditioning For Consolidation Of VGPR Or CR In Myeloma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only